Opportunity Information: Apply for PAR 10 232
Apply for PAR 10 232
- The National Institutes of Health in the food and nutrition health income security and social services sector is offering a public funding opportunity titled "Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173 Research Related to Deafness and Communication Disorders 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Jul 19, 2010 and posted on Jul 19, 2010.
- Applicants must submit their applications by Sep 16, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Special district governments State governments Private institutions of higher education City or township governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities County governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-10-232, titled Innovative Therapies and Tools for Screenable Disorders in Newborns (R21), supports early stage, exploratory research aimed at improving the treatment landscape for disorders relevant to newborn screening. It is sponsored by three NIH institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), and the National Institute on Deafness and Other Communication Disorders (NIDCD). The central focus is on research that advances basic understanding and, more importantly, helps develop therapeutic interventions or enabling tools for conditions already included in newborn screening programs, as well as certain genetic conditions that could realistically become screenable in the near future if effective treatments exist.
A key idea in this announcement is the definition of a "high priority" condition. In this context, a disorder is considered high priority when the main barrier to newborn screening is not the ability to detect it, but the lack of an effective therapy. In other words, if a credible and efficacious treatment were developed, the condition would become a strong candidate for newborn screening because early identification would clearly change clinical outcomes. The FOA is therefore designed to push the field toward interventions that make early detection meaningful, not just technically possible.
The award mechanism is the NIH Exploratory/Developmental Research Grant (R21). R21 grants are typically used for proof of concept efforts, high risk or high reward ideas, and early development work that may be too preliminary for a larger R01. This FOA runs in parallel with two other announcements that cover the same scientific scope but use different mechanisms: PAR-10-230 (R01) and PAR-10-231 (R03). Applicants whose projects are better suited to a small pilot (R03) or a full research project (R01) could pursue those companion FOAs, while PAR-10-232 specifically targets R21-style developmental projects.
In terms of funding, the listed award ceiling is $200,000. The NIH notes that both the size and duration of awards may vary because proposed projects can differ widely in scope and complexity. The total number of awards and the overall amount funded are not fixed in advance; they depend on the number of applications submitted, scientific merit, and the requested budgets and timelines. There is no cost sharing or matching requirement, which means applicants are not required to provide institutional matching funds as a condition of eligibility.
Eligibility is broad and includes many kinds of organizations. Eligible applicants include state, county, city, township, and special district governments; public and private institutions of higher education; nonprofit organizations (including both 501(c)(3) and non-501(c)(3) nonprofits); for-profit organizations (including small businesses); public housing authorities and Indian housing authorities; independent school districts; and federally recognized tribal governments as well as other tribal organizations. The FOA also explicitly includes a wide range of additional eligible entities such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based and community-based organizations, regional organizations, U.S. territories or possessions, eligible federal agencies, and non-U.S. (foreign) organizations.
Administratively, this is a discretionary grant opportunity from the National Institutes of Health. It was posted and created on July 19, 2010, with an original and final closing date of September 16, 2013, and an archive date of October 17, 2013. It is associated with CFDA numbers that reflect the participating NIH institute portfolios: 93.173 (Research Related to Deafness and Communication Disorders), 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), and 93.865 (Child Health and Human Development Extramural Research). The full announcement was hosted on the NIH grants website under the provided link, and the NIH Office of Extramural Research webmaster contact is listed for access or technical issues.
FAQs: NIH PAR-10-232 - Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)
What is PAR-10-232?
PAR-10-232 is a National Institutes of Health (NIH) funding opportunity titled "Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)". It supports early stage, exploratory research intended to improve the treatment landscape for disorders relevant to newborn screening.
What is the main goal of this funding opportunity?
The central goal is to advance research that leads to therapeutic interventions or enabling tools for conditions already included in newborn screening programs, as well as certain genetic conditions that could realistically become screenable in the near future if effective treatments exist.
Which NIH institutes sponsor this opportunity?
This FOA is sponsored by three NIH institutes:
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)
- National Institute on Deafness and Other Communication Disorders (NIDCD)
What kinds of conditions are in scope?
The scope includes disorders relevant to newborn screening, including:
- Conditions already included in newborn screening programs
- Genetic conditions that could become screenable in the near future if effective treatments are developed
What does the FOA mean by a "high priority" condition?
In this announcement, a condition is considered high priority when the key barrier to newborn screening is not detection, but the lack of an effective therapy. The idea is that if a credible and efficacious treatment existed, early identification through newborn screening would clearly improve clinical outcomes and make screening more meaningful.
What grant mechanism is used for PAR-10-232?
PAR-10-232 uses the NIH Exploratory/Developmental Research Grant (R21) mechanism.
What types of projects are typically appropriate for an R21 under this FOA?
R21 grants are generally used for early stage and exploratory projects such as proof-of-concept studies, high risk/high reward ideas, and early development work that may be too preliminary for a larger R01.
Are there related NIH opportunities with the same scientific scope?
Yes. This FOA is described as running in parallel with two companion announcements that cover the same scientific scope but use different mechanisms:
- PAR-10-230 (R01)
- PAR-10-231 (R03)
Applicants whose projects are better aligned with a small pilot (R03) or a full research project (R01) could consider those companion FOAs, while PAR-10-232 targets R21-style developmental projects.
What is the maximum award amount listed for this opportunity?
The listed award ceiling is $200,000.
Are award size and project duration fixed?
No. NIH notes that both the size and the duration of awards may vary because projects can differ widely in scope and complexity.
How many awards will NIH make under this FOA?
The total number of awards is not fixed in advance. Awards depend on factors including the number of applications received, scientific merit, and the requested budgets and timelines.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement described for this opportunity.
Who is eligible to apply?
Eligibility is described as broad and includes many types of organizations, including:
- State, county, city, township, and special district governments
- Public and private institutions of higher education
- Nonprofit organizations (501(c)(3) and non-501(c)(3))
- For-profit organizations, including small businesses
- Public housing authorities and Indian housing authorities
- Independent school districts
- Federally recognized tribal governments and other tribal organizations
- Alaska Native and Native Hawaiian Serving Institutions
- Hispanic-serving institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Faith-based and community-based organizations
- Regional organizations
- U.S. territories or possessions
- Eligible federal agencies
- Non-U.S. (foreign) organizations
Is this a discretionary grant program?
Yes. It is described as a discretionary grant opportunity from the NIH.
When was this opportunity posted?
The opportunity was posted and created on July 19, 2010.
What were the closing dates for PAR-10-232?
The original and final closing date listed is September 16, 2013.
Is this funding opportunity still active?
No. The FOA has an archive date of October 17, 2013, indicating it is no longer active.
What CFDA numbers are associated with this FOA?
This FOA is associated with CFDA numbers reflecting the participating NIH institute portfolios:
- 93.173 - Research Related to Deafness and Communication Disorders
- 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research
- 93.865 - Child Health and Human Development Extramural Research
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants website under the provided link referenced in the opportunity description.
Who is listed as the contact for access or technical issues?
The NIH Office of Extramural Research webmaster is listed as the contact for access or technical issues related to the announcement.
Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services
Next opportunity: ROSES 2010 Earth Surface and Interior
Previous opportunity: Innovative Therapies and Tools for Screenable Disorders in Newborns (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 232
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 232) also looked into and applied for these:
| Funding Opportunity |
|---|
| A GenitoUrinary Development Molecular Anatomy Project (GUDMAP) Database and Website (U01) Apply for RFA DK 10 005 Funding Number: RFA DK 10 005 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Lifestyle Interventions in Overweight and Obese Pregnant Women Consortium (U01) Apply for RFA DK 10 014 Funding Number: RFA DK 10 014 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03) Apply for RFA DK 11 007 Funding Number: RFA DK 11 007 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $50,000 |
| Clinical Trial Planning Grants in Type 1 Diabetes (R34) Apply for RFA DK 11 010 Funding Number: RFA DK 11 010 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 232", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.